SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 206.36+1.4%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tonyt who wrote (27911)2/6/1999 9:45:00 AM
From: Henry Niman  Read Replies (1) of 32384
 
Your speculation was certainly unreasonable by anyone familiar with the FDA approval process. The likelihood that there was a "problem with the drug" after an "approvable letter" had been received and the outstanding issues had been described in a press release and conference call (the outstanding issues were the wording on the label and the data supporting an expiration date), and the advisory committee had voted 8-1 for approval, was absurd at best and intentionally misleading at worst.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News